Press Release Archive
-
Landmark Phase 3 VOYAGER PAD Study of XARELTO® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity RevascularizationLandmark Phase 3 VOYAGER PAD Study of XARELTO® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity RevascularizationXARELTO® has the potential to be the first anticoagulant in 20 years[i] to show a benefit in these high-risk patientsTwo major Phase 3 trials have evaluated XARELTO® vascular dose plus aspirin in treating patients with atherosclerotic disease
-
Janssen Announces Health Canada Approval of CABENUVA™, the First Long-Acting Regimen for the Treatment of HIVJanssen Announces Health Canada Approval of CABENUVA™, the First Long-Acting Regimen for the Treatment of HIVCABENUVA™ offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression
-
Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific SessionJanssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific SessionHighlights include four late-breaking XARELTO® (rivaroxaban) abstractsFour INVOKANA® (canagliflozin) abstracts from the pivotal CREDENCE study will also be presented
-
Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2
-
Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine DevelopmentJohnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine DevelopmentResearch well underway as Janssen scientists collaborate with leading virology laboratory led by Dan Barouch, M.D., Ph.D.
-
Johnson & Johnson Business Continuity Statement (3/19)Johnson & Johnson Business Continuity Statement (3/19)
-
Janssen Announces Results of Phase 3 Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment Regimen of Rilpivirine And Cabotegravir through 96 WeeksJanssen Announces Results of Phase 3 Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment Regimen of Rilpivirine And Cabotegravir through 96 WeeksFLAIR Phase 3 study demonstrated patient satisfaction and preference for the long-acting injectable regimen over daily oral therapy
-
Janssen Announces 48-week Results of Phase 3b Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment of Rilpivirine and Cabotegravir Administered Every Two MonthsJanssen Announces 48-week Results of Phase 3b Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment of Rilpivirine and Cabotegravir Administered Every Two MonthsATLAS-2M Phase 3 study demonstrated patient preference over daily oral therapy for the every-two-month administration of the long-acting injectable regimen
-
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung CancerJanssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung CancerJNJ-6372, a dual-targeting EGFR-MET bispecific antibody, is being investigated for adults with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion mutations
-
European Medicines Agency Grants PRIME and Advanced Therapy Medicinal Product Designations to Janssen’s RPGR Gene Therapy for X-Linked Retinitis PigmentosaEuropean Medicines Agency Grants PRIME and Advanced Therapy Medicinal Product Designations to Janssen’s RPGR Gene Therapy for X-Linked Retinitis PigmentosaOnly RPGR gene therapy program to receive PRIME designation
Designations will accelerate the regulatory review timeline of this potential gene therapy for European patients living with X-linked retinitis pigmentosa